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ABSTRACT 
Over the past 30 years, the status of diabetes has changed from being measured as a kind disorder of the old to one of the main causes of 
morbidity and mortality disturbing the childhood and middle aged people. It is essential to note that the increase in prevale nce is seen in all six 
populated continents of the globe. Diabetes is deadly disease in both developed and developing countries. Indigofera is a varied genus that has 
shown unique characteristics making it an interesting candidate as a potential perennial crop. Specifically, there is diverse variation among 
species with a number of unique characteristics. Entire plants of I. astragalina were collected from Tiruchengode, Tamilnadu. The plant was 
authenticated by Dr. G.V.S. Murthy, Joint Director, Botanical Survey of India, Coimbatore, Tamilnadu, India. The extraction yield of the extracts 
from plant species is vastly depends on the solvent polarity, which find out both qualitatively and quantitatively the extracted compounds. 
Ethanol and water are the commonly used solvent for the extraction because of their low toxicity and high extraction yield with the advantage 
of modulating the polarity of the solvent by using mixtures at different ratios (Jackson et al, 1996). Ethanol soluble fractions were analyzed by 
TLC. These fractions constituted of mainly nonvolatile mixtures of compounds. The visualizations were aided by either observing the TLC under 
an UV lamp or by exposing the developed TLC plates to iodine vapor. The plant extracts at both the dose level of 200 and 400 mg/kg registered 
79.87 to 85.83 mg/dl of fasting blood glucose level at the end of 10h of the study, while the standard drug, glibenclamide showed 71.63 mg/dl 
at the same time, with a low degree of significance while compared with the solvent treated group.  
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INTRODUCTION 
Diabetes Mellitus Scenario in World 
The occurrence of diabetes is hastily rising all over the world 
at a frightening rate (Huizinga and Rothman, 2006). Over the 
past 30 years, the status of diabetes has changed from being 
measured as a kind disorder of the old to one of the main 
causes of morbidity and mortality disturbing the childhood 
and middle aged people. It is essential to note that the 
increase in prevalence is seen in all six populated continents 
of the globe. Diabetes is deadly disease in both developed 
and developing countries. In 2000, there were a probable 
175 million people with diabetes universal and by 2030, the 
projected estimate of diabetes is 354 million (Wild et al., 
2004). The worldwide increase in the popularity of diabetes 
is owed to population growth, aging, urbanization and an 
augment of obesity and physical inactivity. The prime 
determinants of the epidemic are the rapid epidemiological 
transition associated with alteration in dietetic patterns and 
reduced physical activity. Unlike in the West, wherever older 
populations are mainly affected, the burden of diabetes in 
Asian countries is excessively high in young to middle-aged 
adults (Chan et al, 2009; Ramachandran et al, 2010). 
Healthcare expenditures on diabetes are expected to account 
for 11.6% of the total healthcare expenditure in the world in 
2010. Expected global healthcare expenditures to treat and 
avert diabetes and its complications are expected to total as a 
minimum 376 billion U.S. Dollars (USD) in 2010. By 2030, 
this number is expected to go above some USD490 billion 
(IDF Diabetes Atlas, 2009) 
Medication or Chemical-Induced Diabetes 
Drug-induced diabetes occurs due to a variety of drugs and 
mechanisms (Comi, 2004). An underlying and often 
unsuspected abnormality in carbohydrate metabolism in the 
patient or a family history of diabetes greatly increases the 
risk for developing drug induced diabetes. A lot of drugs can 
damage insulin secretion. These drugs can not cause diabetes 
by themselves, except they may impulsive diabetes in 
individuals with insulin resistance. 
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Indigofera astragalina 
Indigofera is a varied genus that has shown unique 
characteristics making it an interesting candidate as a 
potential perennial crop. Specifically, there is diverse 
variation among species with a number of unique 
characteristics. Some examples of this diversity include 
differences in pericarp thickness, fruit type, and flowering 
morphology. The unique characteristics it has displayed 
include potential for mixed smallholder systems with at least 
one other species and a resilience that allows for constant 
nitrogen update despite varying conditions. 
 
 
 
Fig-1: Plant of Indigogera astragalina 
 
MATERIAL AND METHODS: 
Plant Selection: Drug discovery from medicinal plants has 
evolved to include numerous fields of inquiry and various 
methods of analysis. The process typically begins with a 
botanist, ethno botanist, ethnopharmacologist, or plant 
ecologist who identifies the plant of interest. Collection may 
involve species with known biological activity for which 
active compound(s) have not been isolated (e.g., 
traditionally used herbal remedies) or may involve taxon 
collected randomly for a large screening program. On the 
basis of intensive literature survey; I. astragalina was 
selected for present study. 
Collection and identification: 
Entire plants of I. astragalina were collected from 
Tiruchengode, Tamilnadu. The plant was authenticated by 
Dr. G.V.S. Murthy, Joint Director, Botanical Survey of India, 
Coimbatore, Tamilnadu, India. A voucher specimen is 
preserved in our laboratory for future reference (Voucher 
No.: PCIAS 007). 
Preparation of plant material: 
The fruits of plant were shade dried, reduced to coarse 
powder with the help of grinder and stored in airtight 
container till further use.  
Extraction and fractionation: 
The extraction yield of the extracts from plant species is 
vastly depends on the solvent polarity, which find out both 
qualitatively and quantitatively the extracted compounds. 
Ethanol and water are the commonly used solvent for the 
extraction because of their low toxicity and high extraction 
yield with the advantage of modulating the polarity of the 
solvent by using mixtures at different ratios (Jackson et al, 
1996). The plant materials (1 kg) were initially defatted with 
petroleum ether and then extracted with alcohol and water 
using a Soxhlet apparatus. The yield of the plant extracts 
ethanol (95%) and aqueous measured about 20 g each after 
evaporating the solvent using water bath. The standard 
extracts obtained from Indigofera astragalin were then 
stored in a refrigerator at 4°C for further use for 
phytochemical investigation and pharmacological screening 
(Akueshi et al, 2002). 
Preparation of plates:  
Slurry of silica gel G and distilled water was prepared in a 
pestle with continuous triturating with mortar. The slurry 
was spread evenly on clean grease free glass plates. The 
plates were dried in air and thereafter heated in oven at 110 
0C for about 30 minutes to activate them23. 
Preparation of samples: 
Approximately 10 mg of material was dissolved in respective 
solvents and was used for spotting on TLC plates. 
Application of samples on TLC plates:  
Samples were applied on the TLC plates with the help of a 
capillary tube at a distance of about 0.5 cm from the 
developing solution. The solvent from the plate was 
removed by air-drying and position of the spot was marked. 
Saturation of TLC chamber:  
The inner wall of the chamber was lined with filter paper on 
three sides, the solvent system was poured up to a height of 
about 1 cm from the base, grease was applied on the rim of 
the chamber and it was covered with a glass plate. The 
chamber was allowed to stand for about 30 minutes and by 
that time the filter paper inside the chamber was completely 
drenched by the solvent system, making the chamber 
completely and evenly saturated with solvent system. 
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Development of TLC plates: The plates were placed 
vertically into a solvent vapor saturated TLC chamber and 
allowed to develop till the mobile phase had moved about 
80% from the spotting line; the plate was removed from the 
developing chamber and dried.  
Detection of TLC plates: The eluted spots, representing 
various fractions/compounds, were visualized by different 
detection methods. 
i. The plate were exposed to iodine vapor and observed. 
The TLC profile was examined to determine variation in 
band size and color intensity between the Ethanolic extract 
and its two fraction .The observation indicate that variations 
are present amongst Ethanolic extract, Ethanolic fraction, 
Hexane fraction and chloroform fraction. The TLC study was 
done by using different solvent system for each fraction 
separately and the compounds were detected by sun light, in 
iodine vapours, vanillin sulfuric acid reagent and long UV. 
Optimization of solvent system:  
Ethanol soluble fractions were analyzed by TLC. These 
fractions constituted of mainly non volatile mixtures of 
compounds. The visualizations were aided by either 
observing the TLC under an UV lamp or by exposing the 
developed TLC plates to iodine vapor. The TLC was 
repeatedly improved by changing the solvent systems until a 
system that gave the best separation was obtained.  
Column Chromatography (CC):52 
Column chromatography is an example for liquid-solid 
chromatography.  It operates on the principle that different 
substances will “adsorb” or adhere onto the surface of fine 
particles of a solid adsorbent (e.g., alumina or silica gel).  
Intermolecular forces, which vary in strength according to 
their type, cause organic molecules to bind to the stationary 
phase.  The stronger the intermolecular force, the stronger 
the binding to the stationary phase, the longer the 
compound takes to elute from the column. Stationary phase, 
the longer the compound takes to elute from the column. 
Antidiabetic of I. Astragalina: 
Animals: 
Healthy adult Male albino Wistar rats, weighing 150–200 g 
and Swiss albino mice, weighing 20–25 g were used for the 
Screening methods. 
Investigational model for induction of diabetes: 
Diabetes was induced by intra-peritoneal injection of 
Alloxan monohydrate (150 mg/kg b.w.) dissolved in the in 
normal saline (Viana et al, 2004). Blood was withdrawn (0.1 
ml) from the tip of the tail of each rat under mild ether 
anaesthesia. The blood glucose level was checked before 
alloxanisation and after alloxanisation regularly in 24h 
intervals. Animals were considered diabetic when the blood 
glucose level was raised beyond 200 mg/100 ml of blood. 
This condition was observed at the end of 72 h after 
alloxanisation. 
Preparation of Interventions 
The measured quantity of extracts and fractions of 
Indigofera astragalin and the standard drug glibenclamide (5 
mg/kg) was suspended in 25% Tween-20 in distilled water. 
The solvent, test samples and standard drugs were 
administered by oral route based on dose and corresponding 
weight of the animals. For oral administration of test, 
standard as well as Solvent Feeding needle no 21 was used. 
Maintenance of animals and Exposure Conditions 
Earlier to the experiments, the selected animals were housed 
in acrylic cages in standard environmental conditions 
(conditions (temp: 20–25 0C; relative humidity: 45-55 % 
under 12 h light/dark cycle), fed with standard rat feed for 1 
week in order to adapt to the laboratory conditions and 
water ad libitum. They were fasted overnight (12 h) before 
experiments, but were allowed free access to water. Six 
animals were used for each group of study. All the 
experiments on animals were conducted in accordance with 
the internationally accepted principles for laboratory animal 
use and as per the experimental protocols duly approved by 
the Institutional Ethical Committee. 
Blood glucose level determination  
Fasting blood glucose concentration was determined using a 
Glucometer (Optium), based on the glucose oxidase method. 
Blood samples were collected from the tip of tail at the 
defined time patterns (Aslan et al, 2007a, Aslan et al, 2007b) 
Antihyperglycemic activity of extracts in glucose-loaded 
animals (oral glucose tolerance test) 
The oral glucose tolerance test (OGTT) measures the body's 
ability to use main source of energy i.e. glucose. OGTT is to 
simplify and facilitate the diagnosis of diabetes (Luzi, 1998). 
This method is frequently referred to as physiological 
induction of diabetes mellitus because the blood glucose 
level of the animal is fleetingly increased with no damage to 
the pancreas. An oral glucose tolerance test (OGTT) was 
performed on diabetic rats by feeding glucose (5 g/kg) per 
os. Animals were deprived of food 18 h before and during 
the experiment, but were allowed free access to water. They 
were divided into 7 groups of 6 rats each. Group I served as 
normal control, Group II served as solvent control and 
received only vehicle (Tween + water - 2 ml/kg b.w.) 
through the oral route. Group III received glibenclamide (5 
mg/kg b.w.). Groups IV to VII received the alcohol and 
aqueous extracts of Indigofera astragalin at a dose of 200 
and 400 mg/kg b.w., respectively, through oral route. The 
blood glucose level was determined before drug and glucose 
administration (−1 and 0 h, respectively) and subsequently 
at 0.5, 1, 2 and 3h after. 
RESULTS AND DISCUSSION: 
Preliminary phytochemical study of the I. astragalin 
extracts/fractions 
The medicinal plants are useful for healing as well as for 
curing of human diseases because of the presence of 
phytochemical constituents. The preliminary phytochemical 
screening was carried out to assess the qualitative chemical 
composition of crude extracts and fractions from I. 
astragalin by using precipitation and coloration reaction to 
identify the major natural chemical groups (Harborne, 1998; 
Kokate et al., 2003). General reactions in this analysis 
revealed the presence or absence of these compounds in the 
crude extracts and fractions tested. Summary of preliminary 
phytochemical screening of different extracts and fractions 
is depicted in Table-1. 
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Table-1: Phytochemical screening of extracts and fractions of I. astragalin 
Chemical constituents  Chemical Test Extracts/Fractions 
Ethanol 
extract 
Aqueous 
extracts 
Chloroform 
fraction 
Aqueous 
fraction 
Alkaloids Mayer’s  + + + + 
Dragendorff’s + + + + 
Wagner’s  - - - - 
Hager’s  + + + + 
saponin Foam  - + - - 
Haemolytic  - - - - 
Phenolic compounds and 
Tannins 
Ferric Chloride  + + + + 
Gelatin  - - -  
Lead acetate test + + + + 
Proteins Million’s  + - + - 
Biuret  + + + - 
Xanthoprotein  - - - - 
Flavonoids Ferric Chloride  + + - + 
Shinoda  - - - - 
Lead Acetate  + + + + 
Glycoside  Baljet’s  - - - - 
Legal’s  - - - - 
Borntrager’s  - - - - 
Killer killani  - - - - 
Fixed oil Spot - - - - 
Carbohydrate Molisch’s  - - - - 
Fehling’s  + + + + 
Benedict’s  - - - - 
Barfoed’s  + + + + 
Cobalt-chloride  - - -  
Gums and mucilage  Swelling Index - - - - 
Amino Acids Ninhydrin  - - - - 
Tyrosin  - - - - 
Tryptophan - - - - 
Sterols and triterpenes Liebermann-Burchard’s  + + + - 
Salkowski’s  + - + - 
Key (+) = Presence, (-) = Absent 
 
Effect of various extracts of Indigofera astragalin on 
Blood Glucose Level of normoglycaemic rats 
(hypoglycemic activity)  
The effects of ethanol and aqueous extracts of aerial parts of 
I. astragalin on fasting blood glucose levels of normal rats are 
presented in table 2. The plant extracts at both the dose level 
of 200 and 400 mg/kg registered 79.87 to 85.83 mg/dl of 
fasting blood glucose level at the end of 10h of the study, 
while the standard drug, glibenclamide showed 71.63 mg/dl 
at the same time, with a low degree of significance while 
compared with the solvent treated group. The percentage 
change of blood sugar of test extracts treated groups at the 
end of 10 h showed 3 to 12% fall when compared with initial 
BGL in a dose dependent manner. The potency order of the 
test extracts towards the falling of BGL is an aqueous extract 
followed by ethanolic extract.  
Effect of various extracts of Indigofera astragalin on BGL 
of glucose loaded hyperglycemic rats (oral glucose 
tolerance test, OGTT) 
The effect of the test extracts on blood glucose level (BGL) in 
OGTT is depicted in Table 3. The ethanol and aqueous 
extracts at 200 mg/kg dose level registered 92.13, 95.50 
mg/dl at the end of 3 h of the study, while it was 91.50, 96.53 
mg/dl with dose level of 400 mg/kg. However, at the same 
time the standard drug glibenclamide at 5mg/kg showed 
62.51 mg/dl of BGL. However the calculated percentage fall 
of BGL demonstrated 6.22, 18.26 and 14.73, 24.79% with 
respect to 200 and 400 mg/kg dose levels when measured at 
the end of the 3 h of the study, while at the same time 
glibenclamide showed a 30.10% fall of BGL. The progressive 
fall of BGL of the test extracts, in the different test hour 
showed a statistical significant of p<0.05 to p<0.01, while 
analyzed by using ANOVA followed by Dunnett’s t-test. The 
aqueous extract possesses more BG lowering potency than 
that of the ethanol extract in a dose dependent manner. The 
test extracts at tested dose levels also showed a significant 
fall of BGL while compared with solvent control group during 
the study period of 30, 60 and 120 min. 
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       Table-2: Effect of ethanolic and aqueous extracts of I. astragalin on blood glucose level in normoglycemic rats. 
Groups 
Treatment 
and dose 
Blood Glucose Levels(mg/dl) % 
decrease 
at 10 hrs 0 hr 1 hr 2 hr 4 hr 6 hr 8 hr 10 hr 
I. 
Solvent  
Control  
(Tween + 
Water) 
94.6 ± 
1.1 
87.2 ± 
4.62 
91.43 ± 
1.86 
89.56 ± 
0.81 
91.58 ± 
2.23 
89.66 ± 
0.46 
92.67 ± 
3.22 
-- 
II. 
Glibenclamide 
(5mg/kg) 
91.43 ± 
1.31 
81.22 ± 
2.63 
67.53 ± 
2.34* 
58.12 ± 
2.61** 
54.72 ± 
2.44** 
73.83 ± 
1.42** 
71.63 ± 
2.81** 
21.65 
III 
Eth. Ext.  
(200mg/kg) 
89.13 ± 
1.2 
87.8 ± 
1.1 
86.93 ± 
2.65 
86.73 ± 
1.46 
86.57 ± 
1.43 
86.29 ± 
0.89* 
85.83 ± 
1.51 
3.70 
IV 
Eth. Ext.  
(400mg/kg) 
88.4 ± 
2.43 
87.31 ± 
2.16 
86.13 ± 
1.87 
85.78 ± 
1.67 
84.97 ± 
2.69 
84.11 ± 
1.43* 
82.21 ± 
2.49* 
7.0 
V 
Aq. Ext. 
(200mg/kg) 
92.53 ± 
1.27 
91.46 ± 
1.68 
89.88 ± 
1.09 
87.19 ± 
0.91 
86.07 ± 
2.13 
85.78 ± 
1.18* 
83.66 ± 
1.89* 
9.58 
VI. 
Aq. Ext. 
(400mg/kg) 
91.18 ± 
0.93 
87.19 ± 
0.78 
85.71 ± 
2.61 
85.23 ± 
1.37 
84.83 ± 
2.38* 
83.11 ± 
1.21** 
79.87 ± 
2.73** 
12.40 
Values are expressed in MEAN ± S.E.M of six animals. One Way ANOVA followed by Dunnet’s t-test (t-value denotes statistical 
significance at * p <0.05, and ** p <0.01 respectively, in comparison to group-I). 
 
Table-3: Effect of ethanolic and aqueous extracts of I. astragalin on oral glucose tolerance in normal rats 
Gr. 
Treatment 
and dose 
Blood glucose concentration (mg/dl) 
% decrease 
at end of 3hr 0 min 30 min 60 min 120 min 180 min 
I 
Normal 
Control 
83.75 ± 0.47 86.50 ± 0.84 88.50 ± 1.56 83.50 ± 0.98 86.50 ± 1.47 -- 
II 
Solvent 
control 
90.50 ± 0.64 135.52 ± 0.64** 118.83 ± 0.85** 98.50 ± 0.61** 91.50 ± 0.24** -- 
III 
Glibenclamide 
(5mg/kg) 
89.43 ± 0.40 95.50 ± 1.04** 81.53 ± 0.91** 72.50 ± 0.64** 62.51 ± 0.66** 30.10 
IV 
Eth. Ext. 
(200mg/kg) 
83.62 ± 1.78 98.25 ± 0.85** 97.61 ± 1.91** 93.50 ± 1.63** 92.13 ± 0.95 6.22 
V 
Eth. Ext. 
(400mg/kg) 
87.50 ± 0.89 107.31 ± 1.37** 102.32 ± 1.10** 94.50 ± 0.54* 91.50 ± 0.54 14.73 
VI 
Aq. Ext. 
(200mg/kg) 
91.50 ± 0.64 116.84 ± 1.10** 109.83 ± 0.85** 102.65 ± 1.91* 95.50 ± 0.64* 18.26 
VII 
Aq. Ext. 
(400mg/kg) 
84.87 ± 0.91 128.36 ± 0.85** 117.36 ± 1.70 103.51 ± 0.77** 96.53 ± 1.27** 24.79 
Values are expressed in MEAN ± S.E.M of six animals. One Way ANOVA followed by Dunnet’s t-test (t-value denotes statistical 
significance at * p <0.05, ** p <0.01 respectively, in comparison to group-II) 
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Fig.2: Effect of ethanolic and aqueous extracts of I. astragalin on oral glucose tolerance in normal rats 
CONCLUSION 
The present investigations concluded that the ethanolic and 
aqueous extracts of aerial parts of I. astragalin endowed with 
potential antidiabetic activity which could be attributed by 
their possible multiple effects on both pancreatic and extra-
pancreatic site by influencing either the metabolism and/or 
absorption of glucose, which in turn also influence the lipid 
metabolism. 
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